Company Intelligence

Due diligence intelligence for active companies. Signal-scored across geopolitical exposure, regulatory risk, and sector tailwinds — ranked by composite risk/opportunity score.

All energy technology financials healthcare industrials consumer materials utilities defense semiconductors mining pharma telecom shipping agriculture real_estate

All postures ✦ Opportunities ⚠ Risks

Themes for pharma

💊Pharma Supply Chain Reshoring

Total Tracked

Opportunities

Risk Flags

AZN +37

Top Score

✦

Opportunities

(12)

Ticker

Company

Sector

Action

Flag

Score

AZN

🇬🇧AstraZeneca PLC

AstraZeneca's oncology franchise (Tagrisso, Enhertu, Imfinzi

AstraZeneca's oncology franchise (Tagrisso, Enhertu, Imfinzi) is delivering accelerating growth as c

AstraZeneca's oncology franchise (Tagrisso, Enhertu, Imfinzi) is delivering accelerating growth as combination trials expand label coverage

pharma

EARLY

🇬🇧

LLY

🇺🇸Eli Lilly and Company

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) contin

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) continues to take share from Novo Nordisk as s

Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) continues to take share from Novo Nordisk as supply normalizes and oral GLP-1 orforgli

pharma

EARLY

🇺🇸

+37—

NVS

🇨🇭Novartis AG

Novartis post-Sandoz spinoff is a pure-play innovative pharm

Novartis post-Sandoz spinoff is a pure-play innovative pharma with strong cardiovascular (Entresto,

Novartis post-Sandoz spinoff is a pure-play innovative pharma with strong cardiovascular (Entresto, Leqvio) and oncology (Pluvicto, Kisqali)

pharma

EARLY

🇨🇭

+22—

SNY

🇫🇷Sanofi

Sanofi captures the majority economics of Dupixent post-2025

Sanofi captures the majority economics of Dupixent post-2025 cost-sharing reset with Regeneron, prov

Sanofi captures the majority economics of Dupixent post-2025 cost-sharing reset with Regeneron, providing structural earnings growth. Beyfor

pharma

EARLY

🇫🇷

+22—

VRTX

🇺🇸Vertex Pharmaceuticals Incorporated

Vertex's vanzacaftor triple CF combination launched smoothly

Vertex's vanzacaftor triple CF combination launched smoothly and improves both efficacy and royalty

Vertex's vanzacaftor triple CF combination launched smoothly and improves both efficacy and royalty economics. Suzetrigine non-opioid pain f

pharma

EARLY

🇺🇸

+22—

RPRX

🇺🇸Royalty Pharma plc

Royalty Pharma is the largest buyer of biopharmaceutical roy

Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing diversified non-operat

Royalty Pharma is the largest buyer of biopharmaceutical royalties, providing diversified non-operating exposure to top-selling drugs (Trele

pharma

EARLY

🇺🇸

+22—

AMGN

🇺🇸Amgen Inc.

Amgen's MariTide injectable GLP-1 with monthly dosing offers

Amgen's MariTide injectable GLP-1 with monthly dosing offers a credible third entrant to challenge L

Amgen's MariTide injectable GLP-1 with monthly dosing offers a credible third entrant to challenge Lilly/Novo if Phase 3 data reads out clea

pharma

EARLY

🇺🇸

+22—

RHHBY

🇨🇭Roche Holding AG

Roche's CT-388 dual incretin obesity asset offers a credible

Roche's CT-388 dual incretin obesity asset offers a credible Phase 3 entry into the GLP-1 category b

Roche's CT-388 dual incretin obesity asset offers a credible Phase 3 entry into the GLP-1 category by 2027. Vabysmo continues to take retina

pharma

EARLY

🇨🇭

+22—

DSNKY

🇯🇵Daiichi Sankyo Company, Limited

Daiichi Sankyo is the global leader in antibody-drug conjuga

Daiichi Sankyo is the global leader in antibody-drug conjugates (ADCs) with Enhertu (HER2) as the fl

Daiichi Sankyo is the global leader in antibody-drug conjugates (ADCs) with Enhertu (HER2) as the flagship asset alongside AstraZeneca, plus

pharma

EARLY

🇯🇵

+22—

CSLLY

🇦🇺CSL Limited

CSL is the global leader in plasma-derived therapies (immuno

CSL is the global leader in plasma-derived therapies (immunoglobulins, albumin) with a leading flu v

CSL is the global leader in plasma-derived therapies (immunoglobulins, albumin) with a leading flu vaccine business (Seqirus) and the Vifor

pharma

EARLY

🇦🇺

+22—

GILD

🇺🇸Gilead Sciences Inc.

Gilead's lenacapavir long-acting HIV PrEP is a category-rede

Gilead's lenacapavir long-acting HIV PrEP is a category-redefining product approved for twice-yearly

Gilead's lenacapavir long-acting HIV PrEP is a category-redefining product approved for twice-yearly dosing, with strong real-world uptake.

pharma

EARLY

🇺🇸

+22—

ABBV

🇺🇸AbbVie Inc.

AbbVie is past the worst of Humira biosimilar erosion with S

AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory ab

AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory above $24B by 2027. Cerevel and ImmunoGen

pharma

EARLY

🇺🇸

+22—